12 results about "Androgen level" patented technology

The invention discloses a traditional Chinese medicine compound composition for treating androgen-derived alopecia and a preparation method and application thereof. The traditional Chinese medicine compound composition is prepared from cacumen biotae, herba ecliptae, glossy privet fruit, radix polygoni multiflori and radix paeoniae alba according to a specific proportion. And after reflux extraction with 75% ethanol, the skin androgen level (Plt; 0.05) is significantly reduced through local smearing administration, the number of hair follicles is increased to 67 + / -5 / view, and hair regeneration in an alopecia area is promoted. The composition has the advantages of safety, effectiveness, low cost, avoidance of systemic side effects and the like, and is suitable for developing AGA external treatment medicines.

The invention discloses application of ginseng and antler kidney tonifying tablets in preparation of drugs for preventing and / or treating prostatic hyperplasia. The ginseng antler kidney-tonifying tablet has a good treatment effect on prostatic hyperplasia, the treatment effect is remarkable, no operation is needed, the ginseng antler kidney-tonifying tablet belongs to new use of an old medicine, the safety is high, the side effect is small, and the production cost is greatly reduced. The problems that current western medicines for treating benign prostatic hyperplasia are long in medication cycle, large in toxic and side effects and limited in clinical application are solved. Experimental results show that the ginseng and antler kidney-tonifying tablet can reduce the prostate gland coefficient; the androgen level of a prostatic hyperplasia patient is reduced; the gland and glandular cavity expansion and hyperplasia degree of a prostatic hyperplasia patient is improved.

The present invention relates to modified recombinant human MIS protein which has improved cleavage and increased bioactivity and increased potency as compared to wild-type human MIS protein. Other aspects of the invention relate to methods to prevent and treat cancers, such as cancers that express the MIS receptor type II (MISRII) by administering to a subject a composition comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and / or for the treatment of a subject with a disease characterized by excess androgen. Another aspect provides pharmaceutical compositions and kits and methods for use comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with the recombinant MIS protein that lowers the effective dose of the chemotherapeutic agent.

The present invention relates to modified recombinant human MIS protein which has improved cleavage and increased bioactivity and increased potency as compared to wild-type human MIS protein. Other aspects of the invention relate to methods to prevent and treat cancers, such as cancers that express the MIS receptor type II (MISRII) by administering to a subject a composition comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and / or for the treatment of a subject with a disease characterized by excess androgen. Another aspect provides pharmaceutical compositions and kits and methods for use comprising a recombinant human MIS protein. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with the recombinant MIS protein that lowers the effective dose of the chemotherapeutic agent.

The present invention discloses a Chinese medicine composition for treating hyperluteinizing hormone (LH) in polycystic ovary syndrome (PCOS) and its application. The Chinese medicine composition comprises the following raw materials: 10-15 parts of white peony root, 10-30 parts of raw oyster, 10-20 parts of stone cassia seed, 3-15 parts of stir-fried jujube seeds, 3-15 parts of artemisia capillaris, 10-30 parts of daizheshi, 3-15 parts of salvia miltiorrhiza, 3-15 parts of selfheal, 3-12 parts of dodder seed, 3-12 parts of glossy privet fruit, and 3-10 parts of notopterygium wilfordii. The present invention also discloses a preparation method of the above-mentioned Chinese medicine composition and its application in preparing a drug for treating hyperluteinizing hormone (LH) in polycystic ovary syndrome. The Chinese medicine composition of the present invention has the effect of reducing serum LH and androgen levels and promoting menstruation.

The present invention relates to the field of molecular biology technology, and more specifically, to an application of flounder 17β-hydroxysteroid dehydrogenase 12b. The application of flounder 17β-hydroxysteroid dehydrogenase 12b (Hsd17b12b) in regulating the synthesis of sex hormones in flounder. The present invention also discloses an application method for increasing androstenedione levels in the ovary by intraperitoneal injection of a recombinant plasmid of Hsd17b12b in vivo, further demonstrating that the protein can be used to alter androgen levels in the gonads of flounder. The Hsd17b12b of the present invention can be used for research on gonadal differentiation and development in fish such as flounder, and can also provide a basis for screening inhibitors and activators thereof, thereby providing new ideas for single-sex fish farming.

The invention discloses an application of a sheep placenta extract in preparation of a medicine for improving polycystic ovarian syndrome, and relates to the technical field of biological medicine, the medicine is used for improving endocrine disorder and abnormal inflammation caused by the polycystic ovarian syndrome, and particularly for reducing the plasma androgen level and increasing the plasma estrogen level and the plasma progestational hormone level; the level of an inflammatory factor TNF-alpha is reduced, and the level of an inflammatory factor IL-10 is increased. The sheep placenta extract can improve ovarian polycystic lesions caused by polycystic ovarian syndrome (PCOS) in a targeted manner, and experiments show that after intervention of the sheep placenta extract, the number of macroscopic cystic follicles in rat ovary is reduced, the weight of the ovary with abnormal weight gain is remarkably reduced, the cystic follicle ratio in ovarian histopathology detection is greatly reduced, and the sheep placenta extract has a good application prospect. The ratio of the number of the corpus luteum is closer to normal, and the pathological injury of the polycystic ovarian syndrome is repaired from the organ level.

The present application relates to the anti-falling agent, especially to a kind of compound in the preparation of treating androgen alopecia drug application.The present application based on the defects of existing drugs, provide a kind of small molecule compound I that can inhibit AR dimerization into nucleus, it does not affect the content of androgen and androgen receptor in vivo, can avoid the androgen level reduction caused by existing drugs such as non-steroidal antiandrogen on the market, sexual dysfunction, side effect is smaller, it is a kind of safe and effective, can promote androgen alopecia patient hair growth, alleviate androgen alopecia patient hair fine and soft hair follicle atrophy active substance.

The invention discloses a keratin peptide compound with an effect of promoting hair growth and application of the keratin peptide compound, and belongs to the technical field of health food for promoting hair growth. The keratin peptide compound provided by the invention does not have any toxic or side effect; the hair growth of physiological alopecia model mice and androgen alopecia model mice can be effectively promoted, the test mice have no abnormal phenomenon during the test, and the safety is good; on one hand, the health degree of hair follicle cells and scalp can be improved, and a suitable growth environment is provided for hair growth; on the other hand, the absorption and utilization capability of the body on nutrient substances is improved, and raw materials are provided for hair growth; the main hidden danger of causing non-physiological alopecia is radically solved by adjusting the androgen level in the body; meanwhile, the growth period of hair is prolonged, the good effect of promoting hair growth is achieved, and a virtuous circle is formed.

The application discloses a system for predicting and evaluating the probability of in vitro fertilization pregnancy based on androgen response elasticity, which comprises a data acquisition module and an androgen response elasticity calculation module; the data acquisition module is used for acquiring the age of a subject and androgen levels at different stages; and the androgen response elasticity calculation module is used for calculating androgen response elasticity parameters according to the androgen levels at different stages, and obtaining the probability of in vitro fertilization pregnancy during ovary stimulation according to the androgen response elasticity parameters and the age of the subject.

The present invention relates to a propionamide androgen receptor antagonist and a use thereof. The present invention relates to a compound of formula I or a pharmaceutically acceptable salt, solvate, stereoisomer, prodrug, metabolite or isotope derivative thereof, wherein R1, R2, R3, R4, R5, R6, R7, Z, and W are as defined in the description. The present invention further relates to a method for preparing the compound, a pharmaceutical composition comprising the compound, and a use of the compound and the pharmaceutical composition comprising the compound for preventing and / or treating a disease associated with the androgen level.

The invention belongs to the technical field of biology, and particularly discloses an alpha, beta-unsaturated ketene derivative, a preparation method thereof and application of the alpha, beta-unsaturated ketene derivative in skin oil control. The preparation method of the alpha, beta-unsaturated N-acetyl bisamide compound as shown in the formula I comprises the following steps: S1, dissolving 3-cyclopropylmethyl-2, 4-pentanedione and boric acid in ethyl acetate, refluxing and then adding tributyl borate and 4-acetamidobenzaldehyde, S2, stirring and then adding a mixed solution of n-butylamine and ethyl acetate, and carrying out stirring and cooling to obtain the alpha, beta-unsaturated N-acetyl bisamide compound. And S3, filtering to obtain a crude product, and recrystallizing with methanol to obtain the alpha, beta-unsaturated N-acetyl bisamide compound. According to the present invention, the oil control pharmaceutical preparation can significantly inhibit the androgen receptor expression, inhibit the combination of DHT and the androgen receptor, and block DHT-mediated oil secretion, and the treatment of the oil control pharmaceutical preparation has no significant influence on the whole body androgen level.